Compare
20/20 Biolabs, Inc. vs iSpecimen Inc. vs OneMedNet Corp vs Cannabis Bioscience International Holdings, Inc.
| Latest fiscal year | 20/20 Biolabs, Inc. AIDX | iSpecimen Inc. ISPC | OneMedNet Corp ONMD | Cannabis Bioscience International Holdings, Inc. CBIH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-05-31 |
| Revenue | $2.05M | $1.93M | $1.36M | $303.0K |
| Revenue growth (YoY) | +16.7% | -79.2% | +111.4% | +21.8% |
| Gross margin | 29.6% | 1.2% (computed) | -37.0% | 86.8% |
| Operating margin | -162.9% | -465.4% | -711.3% | -139.1% |
| Net margin | -182.8% | -543.7% | -206.1% | -181.1% |
| Net income | -$3.74M | -$10.49M | -$2.80M | -$548.8K |
| EPS (Diluted) | -$0.76 | -$2.28 | -$0.06 | $0.00 |
| Operating cash flow | -$1.92M | -$4.24M | -$7.50M | -$329.6K |
| Free cash flow | n/a | -$4.24M | -$7.52M | n/a |
| Cash & equivalents | $1.03M | $6.88M | $585.0K | n/a |
| Total assets | $4.14M | $9.53M | $2.15M | $31.9K |
| Total liabilities | $4.16M | $6.44M | $5.12M | $1.20M |
| Shareholders' equity | -$19.2K | $3.09M | -$2.96M | -$1.16M |
| Return on year-end equity | n/a | -339.6% | n/a | n/a |
| Shares outstanding | 5.44M | 8.48M | 51.98M | 11.63B |
Revenue, most recent five fiscal years
| Fiscal year | 20/20 Biolabs, Inc. | iSpecimen Inc. | OneMedNet Corp | Cannabis Bioscience International Holdings, Inc. |
|---|---|---|---|---|
| Latest | $2.05M Ended 2025-12-31 | $1.93M Ended 2025-12-31 | $1.36M Ended 2025-12-31 | $303.0K Ended 2025-05-31 |
| 1 year earlier | $1.75M Ended 2024-12-31 | $9.29M Ended 2024-12-31 | $643.0K Ended 2024-12-31 | $248.8K Ended 2024-05-31 |
| 2 years earlier | n/a | $9.93M Ended 2023-12-31 | $1.02M Ended 2023-12-31 | $316.8K Ended 2023-05-31 |
| 3 years earlier | n/a | $10.40M Ended 2022-12-31 | $1.15M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $11.14M Ended 2021-12-31 | n/a | n/a |